News & Updates

For cancer patients with depression, treatment with a single dose of psilocybin appears to yield rapid and meaningful improvements in depressive symptoms, as shown in a phase II study.

Ten-day treatment with vonoprazan 20 mg twice/day plus amoxicillin 750 mg four times/day (VHA-dual) as a first-line therapy for Helicobacter pylori infection results in satisfactory eradication rate of >90 percent, fewer adverse events (AEs), and similar adherence when compared with bismuth quadruple therapy (B-quadruple), results of a study have shown.

Sleep disruption following hospital admission for COVID-19 is associated with dyspnoea, anxiety, and muscle weakness in the CircCOVID cohort sub-study presented at ECCMID 2023.

In vaccinated adults with COVID-19 who are at higher risk of adverse outcomes, treatment with molnupiravir in addition to usual care falls short of reducing the rates of hospitalizations and deaths, as shown by the results of the PANORAMIC study.